Last reviewed · How we verify
NCT05784441
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
Phase 1 trial testing JNJ-90009530 in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma in 21 participants. Participants enrolled and being followed up; not accepting new ones.
6 January 2027
Quick facts
| Lead sponsor | Janssen Research & Development, LLC |
|---|---|
| Phase | Phase 1 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 21 |
| Start date | 6 November 2023 |
| Primary completion | 6 January 2027 |
| Estimated completion | 3 January 2040 |
| Sites | 15 locations across Israel, United Kingdom, United States, Australia |
Drugs / interventions tested
- JNJ-90009530 — full drug profile →
Conditions studied
- Relapsed or Refractory B Cell Non-Hodgkin Lymphoma — all drugs for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma →
Sponsor
Janssen Research & Development, LLC — full company profile →
Who can join
18 and older, any sex, with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: * can a dose of JNJ-90009530 be determined that is safe and well tolerated by patients. * will JNJ-90009530 help patients achieve a response and for how long?
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma.
Pang Y, Ghosh N. · · 2024 · cited 2× · PMID 38711850 · DOI 10.3389/fonc.2024.1396395 -
Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematology.
Ershova A, Goldaeva A, Staliarova A, Bulatov E, et al · · 2025 · cited 1× · PMID 40726984 · DOI 10.3389/fimmu.2025.1592377
Verify or expand the search:
- PubMed search for NCT05784441
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Janssen Research & Development, LLC trials
Trials by the same sponsor.
- NCT07518186 — A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 3 · not yet recruiting
- NCT07309445 — A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC · recruiting
- NCT07499232 — A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease · Phase 3 · not yet recruiting
- NCT07438496 — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus · Phase 3 · recruiting
- NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05784441 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Janssen Research & Development, LLC
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05784441.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing